Fig. 4From: A prospective real-world analysis of erenumab in refractory chronic migrainePercentage of chronic and episodic migraine patients: Percentage of patients who converted into an episodic migraine pattern (< 15 headache days/month) at each month, post-erenumab treatment initiationBack to article page